Abridged and Quarterly Group Financial Report March 2024
Abridged and Quarterly Group Financial Report March 2024AttachmentsAbridged report_March 2024Abridged report_March 2024Group Quarterly report_March 2024Group Quarterly report_March 2024
Month: August 2024
FRO – Q2 2024 Presentation
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Please find enclosed the presentation of Frontline plc´s second quarter 2024 results to be held on the webcast / conference call 30 August, 2024 at 15:00 CET.
This information is subject to the disclosure requirements pursuant to section 5 – 12 of the Norwegian Securities Trading ActAttachmentPresentation Q2 2024
Opthea Reports Full-Year Financial Results and Business Updates
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials
Financings extended cash runway through topline data readout of both trials in CY2025
Leadership appointments in preparation for regulatory filing and launch of sozinibercept
MELBOURNE, Australia, and PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the twelve months ended June 30, 2024, and highlighted recent corporate and clinical updates.
“During the 2024 fiscal year, we made outstanding progress in advancing sozinibercept’s Phase 3 wet AMD program,” said Frederic Guerard,...
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Written by Customer Service on . Posted in Public Companies.
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
Written by Customer Service on . Posted in Public Companies.
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:Morgan Stanley 22nd Annual Global Healthcare Conference in New York City, NY. Company management will host 1×1 meetings on Thursday, September 5, 2024, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat on Friday, September 6, 2024, at 10:00 a.m. ET; and
Cantor Global...
Admiral Markets AS 2024 Unaudited 6 Months Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Admiral Markets AS 2024 Unaudited 6 Months Financial ResultsDespite the low volatility in the financial markets in the first half of 2024, Admiral Markets AS delivered increased trading revenues and positive EBITDA through effective cost control measures.
The Company’s net trading income increased by 21% to EUR 6.9 million (6M 2023: EUR 5.7 million).The Company’s operating expenses decreased by 29% to EUR 6.8 million (6M 2023: EUR 9.6 million).EBITDA was EUR 1.2 million (6M 2023: EUR -3.0 million).Net profit was EUR 0.9 million (6M 2023: EUR -3.9 million).Admirals voluntarily decided in April 2024 to temporarily suspend the onboarding of new customers for Admirals Europe Ltd. This decision is related to Admirals Europe Ltd’s efforts to comply with and adapt to the recommendations of the CySEC...
Admirals Group AS 2024 Unaudited 6 Months Financial Results
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Admirals Group AS 2024 Unaudited 6 Months Financial Results
Despite the low volatility in the financial markets in the first half of 2024, Admiral Markets AS delivered increased trading revenues and positive EBITDA through effective cost control measures. The Group’s net trading income increased by 4% to EUR 22.0 million (6M 2023: EUR 21.1 million).
The Group’s operating expenses decreased by 9% to EUR 22.9 million (6M 2023: EUR 25.2 million).
EBITDA was EUR 0.4 million (6M 2023: EUR -2.9 million).
Net loss was EUR -1.2 million (6M 2023: EUR -4.8 million). Admirals voluntarily decided in April 2024 to temporarily suspend the onboarding of new customers for Admirals Europe Ltd. This decision is related to Admirals Europe Ltd’s efforts to comply with and adapt to the recommendations of the CySEC regulator and affects...
Registration of share capital increase in IDEX Biometrics 30 Aug 2024
Written by Customer Service on . Posted in Public Companies.
Reference is made to the notice on 29 August 2024 regarding settlement of a term payment on a convertible loan by issue of 9,123,333 shares at NOK 0.60 per share.
The share capital has been registered and the shares will be delivered soonest.
Following the issue, the company’s share capital is NOK 50,812,483.20 divided into 338,749,888 shares, each with a nominal value of NOK 0.15.
For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186
About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary...
Extraordinary General Meeting – Nykredit Realkredit A/S
Written by Customer Service on . Posted in Public Companies.
To Nasdaq Copenhagen
Nykredit Realkredit A/S – Extraordinary General Meeting on 30. August 2024
At the Extraordinary General Meeting of Nykredit Realkredit A/S held on Friday 30 August 2024, a resolution passed by the Board of Directors to distribute dividend of DKK 2.200 billion was approved.
Copenhagen, 30 August 2024
Nykredit Realkredit A/SBoard of Directors
ContactIf you have any questions, please contact Press Relations, tel +45 31 21 06 39.AttachmentExtraordinary_General_Meeting_Nykredit Realkredit_A_S_2024-08-30_EN
Berry Corporation Reaffirms a Strong Liquidity Position, Balance Sheet Strength, and Ongoing Free Cash Flow Generation
Written by Customer Service on . Posted in Public Companies.
DALLAS, Aug. 30, 2024 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) is reaffirming its strong liquidity position consisting of $94 million of available borrowing capacity under its reserve-based lending (“RBL”) facility and $11 million of cash as of August 23, 2024, as well as its expectation of significant free cash flow generation continuing during the second half of 2024.
As of August 23, 2024, the Company’s borrowings outstanding under its RBL facility were $22 million, reflecting a reduction of approximately 57%, or $29 million, since the first quarter of 2024. This reduction included the final payment of $20 million made in July on the 2023 Macpherson transaction. The Company maintains $125 million of available borrowing capacity until the RBL facility matures on August 26, 2025. The...